Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Nov 02, 2022 9:54pm
154 Views
Post# 35068567

RE:Shareholder outreach??

RE:Shareholder outreach??Cantor FItzgerald Oncology Conf, IR day with Truist analyst, various IR calls we heard of. They're begining to get back out there, which we have interpreted positively as they wouldn't go out there just to burn the bridges later with bad news. Have to assume the still inconclusive data they've seen so far should be trending positively otherwise they shouldnt' be going out to shareholders.  You'll see it is third on his list. If they get to a solid milestone, they'll need to make #1 on the list. Market is just waiting for the foundation of a true investment thesis around the revenues and pipeline combo. It's compelling if they get there, but dead in the water  until then!

LouisW wrote: Paul said it in the PR. 

We kicked off the third quarter with many exciting developments and spent the remaining period focusing on strategic growth, corporate alignment and shareholder outreach. As our top line results show, our efforts are making a difference,” said Paul Lvesque, President and Chief Executive Officer.

What does shareholder outreach mean? I dont remember they did anything related to shareholder.


<< Previous
Bullboard Posts
Next >>